The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care for ovarian cancer; however, treatment is moving toward a targeted approach with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP inhibitors: AstraZeneca /Merck Sharp & Dohme’s Lynparza, Clovis Oncology’s Rubraca, and GlaxoSmithKline/Tesaro’s Zejula. Multiple combination therapies using immune checkpoint inhibitors are in late-phase development for ovarian cancer, and we anticipate that this drug class will significantly change the indication’s treatment paradigm.

Download the key insights to understand:

• Current market dynamics
• Market constraints
• Current treatment dynamics
• Unmet needs
• Emerging pipeline drugs

• What is the size of the drug-treatable ovarian cancer population, and how will the drug-treatment rates change over time?
• What is the current state of treatment in ovarian cancer? Which drugs are the most important? What are interviewed experts’ insights on current treatment options? What are the main unmet needs in ovarian cancer?
• What are the most promising agents in the pipeline, and how will they shape the future of the ovarian cancer market? What notable therapies are progressing in early-phase trials?
• What is the expected impact of the approvals of Roche / Genentech /Chugai’s Tecentriq, GlaxoSmithKline / Tesaro’s dostarlimab, AstraZeneca’s Imfinzi, Bristol-Myers Squibb / Ono Pharmaceutical’s Opdivo, and Merck Sharp & Dohme’s Keytruda on the ovarian cancer market? What competition will other drug classes present to immune checkpoint inhibitors?
• What are the drivers and constraints in the ovarian cancer market, and how will the market evolve over the forecast period?

If you’d like to see these insights for other markets, visit our report store to see our full range

Note – if your company has a DRG subscription you may be able to access this report by logging in, click here.